Tweet
Diagn Microbiol Infect Dis. 2013 Nov 14. pii: S0732-8893(13)00588-9. doi: 10.1016/j.diagmicrobio.2013.11.003. [Epub ahead of print]
Therapeutic effects of garenoxacin in murine experimental secondary pneumonia by Streptococcus pneumoniae after influenza virus infection.
Fukuda Y, Furuya Y, Nozaki Y, Takahata M, Nomura N, Mitsuyama J.
Source
Research Laboratories, Toyama Chemical Co., Ltd., 2-4-1 Shimookui, Toyama 930-8508, Japan. Electronic address: yoshiko_fukuda@toyama-chemical.co.jp.
Abstract
In a pneumococcal pneumonia murine model following influenza virus infection, garenoxacin was more effective than other fluoroquinolones and demonstrated high levels of bacterial eradication in the lung, low mortality, and potent histopathological improvements. Garenoxacin could potentially be used for the treatment of secondary pneumococcal pneumonia following influenza.
Copyright ? 2013 Elsevier Inc. All rights reserved.
KEYWORDS:
Garenoxacin, In vivo efficacy, Influenza, Secondary bacterial pneumonia, Streptococcus pneumoniae
PMID:
24321356
[PubMed - as supplied by publisher]
Therapeutic effects of garenoxacin in murine experimental secondary pneumonia by Streptococcus pneumoniae after influenza virus infection.
Fukuda Y, Furuya Y, Nozaki Y, Takahata M, Nomura N, Mitsuyama J.
Source
Research Laboratories, Toyama Chemical Co., Ltd., 2-4-1 Shimookui, Toyama 930-8508, Japan. Electronic address: yoshiko_fukuda@toyama-chemical.co.jp.
Abstract
In a pneumococcal pneumonia murine model following influenza virus infection, garenoxacin was more effective than other fluoroquinolones and demonstrated high levels of bacterial eradication in the lung, low mortality, and potent histopathological improvements. Garenoxacin could potentially be used for the treatment of secondary pneumococcal pneumonia following influenza.
Copyright ? 2013 Elsevier Inc. All rights reserved.
KEYWORDS:
Garenoxacin, In vivo efficacy, Influenza, Secondary bacterial pneumonia, Streptococcus pneumoniae
PMID:
24321356
[PubMed - as supplied by publisher]
